Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Exec. Chairman of the Board

CLO, General Counsel & Sec.

Chief Development & Regulatory

President & Chief Commercial

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-savi...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	Exec. Chairman of the Board
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	CEO
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	CLO, General Counsel & Sec.
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	Chief Development & Regulatory
2023-09-21	Premium	back to issuer	Premium	Premium	Premium	President & Chief Commercial
2023-08-09	Premium	sold	Premium	Premium	Premium	CEO
2023-08-09	Premium	sold	Premium	Premium	Premium	Exec. Chairman of the Board
2023-08-09	Premium	sold	Premium	Premium	Premium	Chief Development & Regulatory
2023-08-09	Premium	sold	Premium	Premium	Premium	CLO, General Counsel & Sec.
2023-08-08	Premium	acquired	Premium	Premium	Premium	Chief Development & Regulatory
2023-08-08	Premium	acquired	Premium	Premium	Premium	CLO, General Counsel & Sec.
2023-08-08	Premium	acquired	Premium	Premium	Premium	CEO
2023-08-08	Premium	acquired	Premium	Premium	Premium	Exec. Chairman of the Board
2023-08-08	Premium	acquired	Premium	Premium	Premium	President & Chief Commercial
2023-03-23	Premium	bought	Premium	Premium	Premium	-
2023-03-22	Premium	bought	Premium	Premium	Premium	-
2023-03-21	Premium	bought	Premium	Premium	Premium	-
2023-03-20	Premium	bought	Premium	Premium	Premium	-

PRTK - Paratek Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for PRTK